340 related articles for article (PubMed ID: 25432948)
1. Dimethyl fumarate associated lymphopenia in clinical practice.
Longbrake EE; Cross AH
Mult Scler; 2015 May; 21(6):796-7. PubMed ID: 25432948
[No Abstract] [Full Text] [Related]
2. PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?
Lehmann-Horn K; Penkert H; Grein P; Leppmeier U; Teuber-Hanselmann S; Hemmer B; Berthele A
Neurology; 2016 Jul; 87(4):440-1. PubMed ID: 27343070
[No Abstract] [Full Text] [Related]
3. Herpes simplex virus encephalitis temporally associated with dimethyl fumarate-induced lymphopenia in a multiple sclerosis patient.
Perini P; Rinaldi F; Puthenparampil M; Marcon M; Perini F; Gallo P
Mult Scler Relat Disord; 2018 Nov; 26():68-70. PubMed ID: 30227312
[TBL] [Abstract][Full Text] [Related]
4. Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia.
Kowalec K; Kingwell E; Carruthers R; Marrie RA; Bernatsky S; Traboulsee A; Ross CJD; Carleton B; Tremlett H
BMJ Open; 2017 Jun; 7(5):e016276. PubMed ID: 28576902
[TBL] [Abstract][Full Text] [Related]
5. CMV meningitis associated with dimethyl fumarate therapy-induced lymphopenia in a multiple sclerosis patient.
Kogel AK; Gold R; Schneider R
J Neurol; 2021 Nov; 268(11):4374-4375. PubMed ID: 34175973
[No Abstract] [Full Text] [Related]
6. Diffuse dermatophytosis occurring on dimethyl fumarate therapy.
Greenstein JI
Mult Scler; 2018 Jun; 24(7):999-1001. PubMed ID: 29649923
[TBL] [Abstract][Full Text] [Related]
7. Persistent severe lymphopenia 5 years after dimethyl fumarate discontinuation.
Caldito NG; O'Leary S; Stuve O
Mult Scler; 2021 Jul; 27(8):1306-1308. PubMed ID: 33620273
[TBL] [Abstract][Full Text] [Related]
8. Acute pancreatitis: possible association of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis.
Luo H; Bhatt H; Mohamad S; Uhrik E; Sen S; Mathew T; Yousif A
J Neurol; 2015 Mar; 262(3):779-80. PubMed ID: 25626723
[No Abstract] [Full Text] [Related]
9. Bariatric surgery and dimethyl fumarate-induced lymphopenia in patients with multiple sclerosis.
Andreozzi V; Capuano R; Scannapieco S; Barra F; d'Arco B; Giordano C; Caterino M; De Marca U; Di Filippo F; Di Gregorio M; Barone P
Neurol Sci; 2024 Jun; 45(6):2807-2810. PubMed ID: 38150132
[TBL] [Abstract][Full Text] [Related]
10. The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk.
Khatri BO; Garland J; Berger J; Kramer J; Sershon L; Olapo T; Sesing J; Dukic M; Rehn E
Mult Scler Relat Disord; 2015 Jul; 4(4):377-9. PubMed ID: 26195059
[TBL] [Abstract][Full Text] [Related]
11. Immunological Predictors of Dimethyl Fumarate-Induced Lymphopenia.
Diebold M; Galli E; Kopf A; Sanderson N; Callegari I; Ingelfinger F; Núñez NG; Benkert P; Kappos L; Kuhle J; Becher B; Claassen M; Derfuss T
Ann Neurol; 2022 May; 91(5):676-681. PubMed ID: 35170072
[TBL] [Abstract][Full Text] [Related]
12. Transient hair loss during treatment with dimethyl-fumarate for multiple sclerosis.
Losavio FA; Lucchini M; De Fino C; Mirabella M; Nociti V
Mult Scler Relat Disord; 2016 May; 7():68-9. PubMed ID: 27237761
[TBL] [Abstract][Full Text] [Related]
13. Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate.
Wood CH; Robertson NP; Htet ZM; Tallantyre EC
Mult Scler Relat Disord; 2022 Feb; 58():103492. PubMed ID: 35066268
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate.
Morales FS; Koralnik IJ; Gautam S; Samaan S; Sloane JA
J Neurol; 2020 Jan; 267(1):125-131. PubMed ID: 31583427
[TBL] [Abstract][Full Text] [Related]
15. Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis.
Sainz de la Maza S; Sabin Muñoz J; Pilo de la Fuente B; Thuissard I; Andreu-Vázquez C; Galán Sánchez-Seco V; Salgado-Cámara P; Costa-Frossard L; Monreal E; Ayuso-Peralta L; García-Vasco L; García-Domínguez JM; Martínez-Ginés ML; Muñoz Fernández C; Díaz-Díaz J; Oreja-Guevara C; Gómez-Moreno M; Martín H; Rubio-Flores L; Blasco MR; Villar-Guimerans LM; Aladro Y;
Mult Scler Relat Disord; 2022 Mar; 59():103669. PubMed ID: 35150979
[TBL] [Abstract][Full Text] [Related]
16. Simple parameters from complete blood count predict lymphopenia, adverse effects and efficacy in people with MS treated with dimethyl fumarate.
Baeva ME; Metz LM; Greenfield J; Camara-Lemarroy CR
Mult Scler Relat Disord; 2023 Jun; 74():104699. PubMed ID: 37031552
[TBL] [Abstract][Full Text] [Related]
17. Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis.
Boullosa-Lale S; González-Freire L; Martínez-Martínez L; Crespo-Diz C
Farm Hosp; 2020 Dec; 45(2):73-76. PubMed ID: 33709887
[TBL] [Abstract][Full Text] [Related]
18. Lower lymphocyte counts and older age are associated with reduced multiple sclerosis disease activity during dimethyl fumarate treatment.
Garbo R; Lorenzut S; Del Negro I; Merlino G; Gigli GL; Cargnelutti D; Valente M
Mult Scler Relat Disord; 2021 Apr; 49():102781. PubMed ID: 33524927
[TBL] [Abstract][Full Text] [Related]
19. Legionella infection associated with dimethyl fumarate used for treatment of multiple sclerosis.
Rastas C; Sirignano D; Barner A; Bruno-Murtha LA
J Neurol; 2019 Nov; 266(11):2867-2868. PubMed ID: 31350640
[No Abstract] [Full Text] [Related]
20. An evaluation of dimethyl fumarate for the treatment of relapsing remitting multiple sclerosis.
Valencia-Sanchez C; Carter JL
Expert Opin Pharmacother; 2020 Aug; 21(12):1399-1405. PubMed ID: 32543241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
